(2020) The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study. Daru-Journal of Pharmaceutical Sciences. pp. 507-516.
Text
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia a single centered, retrospective, observational study.pdf Download (861kB) |
Abstract
Background There is no identified pharmacological therapy for COVID-19 patients, where potential therapeutic strategies are underway to determine effective therapy under such unprecedented pandemic. Therefore, combination therapies may have the potential of alleviating the patient's outcome. This study aimed at comparing the efficacy of two different combination regimens in improving outcomes of patients infected by novel coronavirus (COVID-19). Methods This is a single centered, retrospective, observational study of 60 laboratory-confirmed COVID-19 positive inpatients (>= 18 years old) at two wards of the Baqiyatallah Hospital, Tehran, Iran. Patient's data including clinical and laboratory parameters were recorded. According to the drug regimen, the patients were divided into two groups; group I who received regimen I consisting azithromycin, prednisolone, naproxen, and lopinavir/ritonavir and group II who received regimen II including meropenem, levofloxacin, vancomycin, hydroxychloroquine, and oseltamivir. Results The oxygen saturation (SpO2) and temperature were positively changed in patients receiving regimen I compared to regimen II (P = 0.013 andP = 0.012, respectively). The serum level of C-reactive protein (CRP) changed positively in group I (P < 0.001). Although there was a significant difference in platelets between both groups (75.44 vs 51.62, P < 0.001), their change did not clinically differ between two groups. The findings indicated a significant difference of the average length of stay in hospitals (ALOS) between two groups, where the patients under regimen I showed a shorter ALOS (6.97 vs 9.93,P = 0.001). Conclusion This study revealed the beneficial effect of the short-term use of low-dose prednisolone in combination with azithromycin, naproxen and lopinavir/ritonavir (regimen I), in decreasing ALOS compared to regimen II. Since there is still lack of evidence for safety of this regimen, further investigation in our ongoing follow-up to deal with COVID-19 pneumonia is underway. Graphical abstract
Item Type: | Article |
---|---|
Keywords: | Coronavirus disease 2019 Combination therapy Length of stay in hospitals (ALOS) respiratory syndrome lymphocyte subsets cytokine storm wuhan china Pharmacology & Pharmacy |
Page Range: | pp. 507-516 |
Journal or Publication Title: | Daru-Journal of Pharmaceutical Sciences |
Journal Index: | ISI |
Volume: | 28 |
Number: | 2 |
Identification Number: | https://doi.org/10.1007/s40199-020-00353-w |
Depositing User: | مهندس مهدی شریفی |
URI: | http://eprints.bmsu.ac.ir/id/eprint/8753 |
Actions (login required)
View Item |